( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 272 | 進行性骨化性線維異形成症 | 39 |
272. 進行性骨化性線維異形成症
臨床試験数 : 39 / 薬物数 : 38 - (DrugBank : 7) / 標的遺伝子数 : 27 - 標的パスウェイ数 : 95
Showing 1 to 10 of 39 diseases
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05394116 (ClinicalTrials.gov) | November 21, 2022 | 4/5/2022 | The Examination of Safety and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP) The Examination of Safety and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) ... | Phase 3 Randomized, Placebo-Controlled Study to Assess Safety, Tolerability, and Efficacy of Garetosmab in Patients With Fibrodysplasia Ossificans Progressiva Phase 3 Randomized, Placebo-Controlled Study to Assess Safety, Tolerability, and Efficacy of Garetos ... | Fibrodysplasia Ossificans Progressiva | Drug: Garetosmab;Drug: Placebo | Regeneron Pharmaceuticals | NULL | Recruiting | 18 Years | N/A | All | 66 | Phase 3 | Japan;Poland;Spain;United Kingdom |
| 2 | EUCTR2016-002526-36-FR (EUCTR) | 05/07/2022 | 04/07/2016 | Study of an Investigational Drug, Palovarotene, in the prevention of Preosseous Flare-ups in Subjects with Fibrodysplasia Ossificans Progressiva (FOP) Study of an Investigational Drug, Palovarotene, in the prevention of Preosseous Flare-ups in Subject ... | A Phase 2, Open-Label, Efficacy and Safety Study of an RAR?-Specific Agonist (Palovarotene) to Prevent Heterotopic Ossification in Subjects with Fibrodysplasia Ossificans Progressiva (FOP) A Phase 2, Open-Label, Efficacy and Safety Study of an RAR?-Specific Agonist (Palovarotene) to Preve ... | Fibrodysplasia Ossificans Progressiva (FOP) is a rare, severely disabling disease characterized by painful, recurrent episodes of soft tissue swelling (flare-ups) and abnormal heterotopic ossification (HO) in muscles, tendons, and ligaments. Lesions begin in early childhood and lead to progressive ankyloses of major joints with resultant loss of movement. Prognosis is poor and median life expectancy is 40 years. <br>MedDRA version: 19.0;Level: PT;Classification code 10068715;Term: Fibrodysplasia ossificans progressiva;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] Fibrodysplasia Ossificans Progressiva (FOP) is a rare, severely disabling disease characterized by p ... | Product Name: Palovarotene<br>Product Code: Palovarotene<br>INN or Proposed INN: Palovarotene<br>Other descriptive name: Palovarotene Product Name: Palovarotene<br>Product Code: Palovarotene<br>INN or Proposed INN: Palovarotene<br>Oth ... | Clementia Pharmaceuticals Inc. | NULL | Not Recruiting | <an>br>Female: yes Male: yes | 17 | Phase 2 | France | ||
| 3 | NCT05090891 (ClinicalTrials.gov) | May 5, 2022 | 8/10/2021 | To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia O ... | A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and ... | Fibrodysplasia Ossificans Progressiva (FOP) | Drug: INCB000928;Drug: placebo | Incyte Corporation | NULL | Recruiting | 12 Years | 99 Years | All | 60 | Phase 2 | United States;Australia;Brazil;Canada;Chile;China;France;Germany;Italy;Korea, Republic of;Mexico;Netherlands;South Africa;Spain;Turkey;United Kingdom;Russian Federation United States;Australia;Brazil;Canada;Chile;China;France;Germany;Italy;Korea, Republic of;Mexico;Net ... |
| 4 | EUCTR2021-002286-17-FR (EUCTR) | 19/04/2022 | 22/10/2021 | A Phase 2, Randomized Study to Evaluate the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva A Phase 2, Randomized Study to Evaluate the Efficacy, Safety, and Tolerability of INCB000928 in Part ... | A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study toEvaluate the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study toEvaluate the Efficacy, Safety, and T ... | Fibrodysplasia ossificans progressiva <br>MedDRA version: 20.0;Level: PT;Classification code 10068715;Term: Fibrodysplasia ossificans progressiva;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] Fibrodysplasia ossificans progressiva <br>MedDRA version: 20.0;Level: PT;Classification code 1006871 ... | Product Code: INCB000928<br>Other descriptive name: INCB000928 fumarate dihydrate | Incyte Corporation | NULL | Not Recruiting | <an>br>Female: yes Male: yes | 60 | Phase 2 | United States;France;Canada;Brazil;Australia;Russian Federation;Netherlands;Germany;United Kingdom;Korea, Republic of United States;France;Canada;Brazil;Australia;Russian Federation;Netherlands;Germany;United Kingdom;K ... | ||
| 5 | NCT05027802 (ClinicalTrials.gov) | March 14, 2022 | 25/8/2021 | A Rollover Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged =14 Years With Fibrodysplasia Ossificans Progressiva (FOP) Who Have Completed the Relevant Parent Studies. A Rollover Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Fe ... | Rollover Study; Multicentre, Phase III, Open-label Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged =14 Years With Fibrodysplasia Ossificans Progressiva (FOP) Who Have Completed Study PVO-1A-301 or PVO-1A-202/PVO-1A-204 and May Benefit From Palovarotene Therapy. Rollover Study; Multicentre, Phase III, Open-label Study to Further Evaluate the Safety and Efficacy ... | Fibrodysplasia Ossificans Progressiva (FOP) | Drug: Palovarotene | Ipsen | NULL | Recruiting | 14 Years | N/A | All | 87 | Phase 3 | United States;Argentina;Australia;Canada;France;Italy;Sweden;United Kingdom |
| 6 | EUCTR2020-002858-24-SE (EUCTR) | 24/01/2022 | 27/11/2020 | A study assessing the efficacy and safety of an investigational drug called IPN60130 for the treatment of fibrodysplasia ossificans progressiva in participants aged 5 years of age and older A study assessing the efficacy and safety of an investigational drug called IPN60130 for the treatme ... | A Phase 2, two-part, placebo-controlled, parallel-group, double-blind study to assess the efficacy and safety of 2 dosage regimens of oral IPN60130 for the treatment of fibrodysplasia ossificans progressiva in male and female participants 5 years of age and older - FALKON A Phase 2, two-part, placebo-controlled, parallel-group, double-blind study to assess the efficacy a ... | fibrodysplasia ossificans progressiva (FOP) <br>MedDRA version: 20.0;Level: PT;Classification code 10068715;Term: Fibrodysplasia ossificans progressiva;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] fibrodysplasia ossificans progressiva (FOP) <br>MedDRA version: 20.0;Level: PT;Classification code 1 ... | Product Name: IPN60130 10 mg capsules<br>INN or Proposed INN: Not yet available<br>Other descriptive name: (R)-tetrahydrofuran-3-yl 4-(6-(5-(4-ethoxy-1-isopropylpiperidin-4- yl)pyridine-2-yl)pyrrolo[1,2-b]pyridazin-4-yl)piperazine-1-carboxylate sesquisuccinate<br>Product Name: IPN60130 50 mg capsules<br>INN or Proposed INN: Not yet available<br>Other descriptive name: (R)-tetrahydrofuran-3-yl 4-(6-(5-(4-ethoxy-1-isopropylpiperidin-4- yl)pyridine-2-yl)pyrrolo[1,2-b]pyridazin-4-yl)piperazine-1-carboxylate sesquisuccinate Product Name: IPN60130 10 mg capsules<br>INN or Proposed INN: Not yet available<br>Other descriptive ... | Clementia Pharmaceuticals Inc, an Ipsen Company | NULL | Authorised-recruitment may be ongoing or finished | <an>br>Female: yes Male: yes | 90 | Phase 2 | United States;Spain;Russian Federation;Colombia;Italy;United Kingdom;France;Mexico;Canada;Argentina;Brazil;Australia;Germany;Netherlands;Japan;China;Korea, Republic of;Sweden United States;Spain;Russian Federation;Colombia;Italy;United Kingdom;France;Mexico;Canada;Argentina; ... | ||
| 7 | NCT05039515 (ClinicalTrials.gov) | December 1, 2021 | 2/9/2021 | Study to Assess the Efficacy and Safety of 2 Dosage Regimens of Oral IPN60130 for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP). Study to Assess the Efficacy and Safety of 2 Dosage Regimens of Oral IPN60130 for the Treatment of F ... | A Phase 2, Two-part, Placebo-controlled, Parallel-group, Double-blind Study to Assess the Efficacy and Safety of 2 Dosage Regimens of Oral IPN60130 for the Treatment of Fibrodysplasia Ossificans Progressiva in Male and Female Participants 5 Years of Age and Older. A Phase 2, Two-part, Placebo-controlled, Parallel-group, Double-blind Study to Assess the Efficacy a ... | Fibrodysplasia Ossificans Progressiva | Drug: IPN60130;Drug: Placebo | Clementia Pharmaceuticals Inc. | Ipsen | Recruiting | 5 Years | N/A | All | 90 | Phase 2 | United States;Argentina;Australia;Brazil;Canada;China;Colombia;France;Italy;Japan;Korea, Republic of;Mexico;Spain;Sweden;United Kingdom United States;Argentina;Australia;Brazil;Canada;China;Colombia;France;Italy;Japan;Korea, Republic of ... |
| 8 | EUCTR2020-002858-24-ES (EUCTR) | 19/10/2021 | 27/07/2021 | A study assessing the efficacy and safety of an investigational drug called IPN60130 for the treatment of fibrodysplasia ossificans progressiva in participants aged 5 years of age and older A study assessing the efficacy and safety of an investigational drug called IPN60130 for the treatme ... | A Phase 2, two-part, placebo-controlled, parallel-group, double-blind study to assess the efficacy and safety of 2 dosage regimens of oral IPN60130 for the treatment of fibrodysplasia ossificans progressiva in male and female participants 5 years of age and older A Phase 2, two-part, placebo-controlled, parallel-group, double-blind study to assess the efficacy a ... | fibrodysplasia ossificans progressiva (FOP) <br>MedDRA version: 20.0;Level: PT;Classification code 10068715;Term: Fibrodysplasia ossificans progressiva;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] fibrodysplasia ossificans progressiva (FOP) <br>MedDRA version: 20.0;Level: PT;Classification code 1 ... | Product Name: IPN60130 10 mg capsules<br>INN or Proposed INN: not yet available<br>Other descriptive name: (R)-tetrahydrofuran-3-yl 4-(6-(5-(4-ethoxy-1-isopropylpiperidin-4- yl)pyridine-2-yl)pyrrolo[1,2-b]pyridazin-4-yl)piperazine-1-carboxylate sesquisuccinate<br>Product Name: IPN60130 50 mg capsules<br>INN or Proposed INN: Not yet available<br>Other descriptive name: (R)-tetrahydrofuran-3-yl 4-(6-(5-(4-ethoxy-1-isopropylpiperidin-4- yl)pyridine-2-yl)pyrrolo[1,2-b]pyridazin-4-yl)piperazine-1-carboxylate sesquisuccinate Product Name: IPN60130 10 mg capsules<br>INN or Proposed INN: not yet available<br>Other descriptive ... | Clementia Pharmaceuticals Inc, an Ipsen Company | NULL | Authorised-recruitment may be ongoing or finished | <an>br>Female: yes Male: yes | 90 | Phase 2 | United States;Spain;Russian Federation;Colombia;United Kingdom;Italy;France;Mexico;Canada;Argentina;Brazil;Australia;Netherlands;Germany;China;Japan;Sweden;Korea, Republic of United States;Spain;Russian Federation;Colombia;United Kingdom;Italy;France;Mexico;Canada;Argentina; ... | ||
| 9 | NCT04577820 (ClinicalTrials.gov) | October 13, 2021 | 30/9/2020 | Study to Assess the Efficacy and Safety of Garetosmab in Japanese Adult Patients With Fibrodysplasia Ossificans Progressiva (FOP) Study to Assess the Efficacy and Safety of Garetosmab in Japanese Adult Patients With Fibrodysplasia ... | Evaluation of Efficacy and Safety of Garetosmab in Japanese Adult Patients With Fibrodysplasia Ossificans Progressiva Evaluation of Efficacy and Safety of Garetosmab in Japanese Adult Patients With Fibrodysplasia Ossif ... | Fibrodyplasia Ossificans Progressiva (FOP);Heterotopic Ossification (HO) | Drug: garetosmab | Regeneron Pharmaceuticals | NULL | Withdrawn | 18 Years | 60 Years | All | 0 | Phase 3 | NULL |
| 10 | EUCTR2020-002858-24-IT (EUCTR) | 09/06/2021 | 04/06/2021 | A study assessing the efficacy and safety of an investigational drug calledIPN60130 for the treatment of fibrodysplasia ossificans progressiva inparticipants aged 5 years of age and older A study assessing the efficacy and safety of an investigational drug calledIPN60130 for the treatmen ... | A Phase 2, two-part, placebo-controlled, parallel-group, double-blind study to assess the efficacy and safety of 2 dosage regimens of oral IPN60130 for the treatment of fibrodysplasia ossificans progressiva in male and female participants 5 years of age and older - - A Phase 2, two-part, placebo-controlled, parallel-group, double-blind study to assess the efficacy a ... | fibrodysplasia ossificans progressiva (FOP) <br>MedDRA version: 20.0;Level: PT;Classification code 10068715;Term: Fibrodysplasia ossificans progressiva;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] fibrodysplasia ossificans progressiva (FOP) <br>MedDRA version: 20.0;Level: PT;Classification code 1 ... | Product Name: IPN60130 10 mg capsules<br>Product Code: [-]<br>Other descriptive name: (R)-tetrahydrofuran-3-yl 4-(6-(5-(4-ethoxy-1-isopropylpiperidin-4- yl)pyridine-2yl)pyrrolo[1,2-b]pyridazin-4-yl)piperazine-1-carboxylate<br>Product Name: IPN60130 50 mg capsules<br>Product Code: [-]<br>Other descriptive name: (R)-tetrahydrofuran-3-yl 4-(6-(5-(4-ethoxy-1-isopropylpiperidin-4- yl)pyridine-2yl)pyrrolo[1,2-b]pyridazin-4-yl)piperazine-1-carboxylate Product Name: IPN60130 10 mg capsules<br>Product Code: [-]<br>Other descriptive name: (R)-tetrahydro ... | CLEMENTIA PHARMACEUTICALS INC. | NULL | Authorised-recruitment may be ongoing or finished | <an>br>Female: yes Male: yes | 90 | Phase 2 | United States;Spain;Russian Federation;United Kingdom;Italy;France;Mexico;Canada;Argentina;Brazil;Australia;Germany;Netherlands;China;Japan;Sweden;Korea, Republic of United States;Spain;Russian Federation;United Kingdom;Italy;France;Mexico;Canada;Argentina;Brazil;Au ... |